Moreover, this research could support the efficacy of HA inhalation therapy, anti-G-CSF antibody therapy, and G-CSF receptor-targeted antagonistic therapy in patients with COPD. The gene discussed is CSF3R; the disease is chronic obstructive pulmonary disease.